← Eichor
Study identifier: NCT06611176 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Local LevoBupivacaine for Pain Relief After Endoscopic Submucosal Dissection for Esophageal Lesions

Condition: Endoscopic Submucosal Dissection · Levobupivacaine  ·  Sponsor: Laura Boer

PhaseNA
Planned participants88
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Endoscopic submucosal dissection (ESD) is commonly performed for (pre)cancerous lesions in the esophagus. Following ESD, post-procedural chest pain is seen in many patients. Studies have shown that local bupivacaine (BP) into the residual submucosal layer of the resection wound after gastric ESD could reduce post-procedural pain rates effectively. Levobupivacaine (LB) is equipotent to BP regarding analgesic effects, but has a better safety profile. No studies have been performed to evaluate the efficacy of LB after esophageal ESD to reduce pain. Therefore, we want to evaluate the effect on post-procedural pain of local application of LB during esophageal ESD.

This description comes directly from the study's public registry record.

Talk to the study team

Laura S Boer, Degree of medicine  ·  0887550224  ·  l.boer1@antoniusziekenhuis.nl

Always discuss trial participation with your own doctor first.

Locations (3)

UMCGGroningen, NetherlandsRecruiting
St Antonius HospitalNieuwegein, NetherlandsRecruiting
UMCUUtrecht, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06611176